These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35507992)

  • 1. Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study.
    Ergür FÖ; Yıldız M; Şener MU; Kavurgacı S; Ozturk A
    Sao Paulo Med J; 2022; 140(3):372-377. PubMed ID: 35507992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey.
    Erdem HA; Korkma PE; Çağlayan D; Işıkgöz Taşbakan M; Yamazhan T; Taşbakan MS; Sayıner A; Gökengin D
    Turk J Med Sci; 2021 Jun; 51(3):912-920. PubMed ID: 33237663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favipiravir-induced fever in coronavirus disease 2019: A report of two cases.
    Takoi H; Togashi Y; Fujimori D; Kaizuka H; Otsuki S; Wada T; Takeuchi Y; Abe S
    Int J Infect Dis; 2020 Dec; 101():188-190. PubMed ID: 32992014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
    Li J; Zhang C; Wu Z; Wang G; Zhao H
    Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Favipiravir for the Treatment of Coronavirus Disease 2019 in the Setting of Hospitel.
    Surapat B; Kobpetchyok W; Kiertiburanakul S; Arnuntasupakul V
    Int J Clin Pract; 2022; 2022():3098527. PubMed ID: 35685498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences.
    Shiraki K; Sato N; Sakai K; Matsumoto S; Kaszynski RH; Takemoto M
    Pharmacol Ther; 2022 Jul; 235():108121. PubMed ID: 35121001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of risk factors for uric acid elevation in COVID-19 patients treated with favipiravir.
    Hanai Y; Yoshizawa S; Matsuo K; Uekusa S; Miyazaki T; Nishimura K; Mabuchi T; Ohashi H; Ishii Y; Tateda K; Yoshio T; Nishizawa K
    Diagn Microbiol Infect Dis; 2022 Apr; 102(4):115640. PubMed ID: 35193798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers.
    Turan DB; Menteş M; Özel Y; Şerefhanoğlu K; Aydoğan B; İbil N; Güneşdoğdu F; Orucova HM; Saltürk C; Çelik H
    Braz J Infect Dis; 2022; 26(1):102328. PubMed ID: 35139366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19.
    Yamazaki S; Suzuki T; Sayama M; Nakada TA; Igari H; Ishii I
    J Infect Chemother; 2021 Feb; 27(2):390-392. PubMed ID: 33402301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies.
    Hung DT; Ghula S; Aziz JMA; Makram AM; Tawfik GM; Abozaid AA; Pancharatnam RA; Ibrahim AM; Shabouk MB; Turnage M; Nakhare S; Karmally Z; Kouz B; Le TN; Alhijazeen S; Phuong NQ; Ads AM; Abdelaal AH; Nam NH; Iiyama T; Kita K; Hirayama K; Huy NT
    Int J Infect Dis; 2022 Jul; 120():217-227. PubMed ID: 35470021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Effect of Favipiravir on QT Intervals in COVID-19 Patients with and without Diabetes Mellitus.
    Dogan M; Baykiz D; Yilmaz I; Hacioglu Kasim FB; Bilir BE; Bilir B
    J Coll Physicians Surg Pak; 2024 Jun; 34(6):659-666. PubMed ID: 38840347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favipiravir for the treatment of COVID-19 pneumonia: Can we predict the response to treatment?
    Sayiner A; Erdem HA; Korkmaz Ekren P; Tasbakan S; Basoglu OK; Tasbakan MI; Yamazhan T; Gokengin D; Ozhan MH
    J Infect Dev Ctries; 2022 Mar; 16(3):422-426. PubMed ID: 35404846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Characteristics and Outcomes of Pediatric COVID-19 Pneumonia Treated with Favipiravir in a Tertiary Care Center.
    Sitthikarnkha P; Phunyaissaraporn R; Niamsanit S; Techasatian L; Saengnipanthkul S; Uppala R
    Viruses; 2024 Jun; 16(6):. PubMed ID: 38932238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment.
    Çınarka H; Günlüoğlu G; Çörtük M; Yurt S; Kıyık M; Koşar F; Tanrıverdi E; Arslan MA; Baydili KN; Koç AS; Altın S; Çetinkaya E
    Turk J Med Sci; 2021 Aug; 51(4):1624-1630. PubMed ID: 33726482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19.
    Shahrbaf MA; Tabary M; Khaheshi I
    Cardiovasc Hematol Disord Drug Targets; 2021; 21(2):88-90. PubMed ID: 34387172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial.
    Zhao H; Zhang C; Zhu Q; Chen X; Chen G; Sun W; Xiao Z; Du W; Yao J; Li G; Ji Y; Li N; Jiang Y; Wang Y; Zeng Q; Li W; Gong B; Chang X; Zhu F; Jiang X; Li J; Wu Z; Liu Y; Peng P; Wang G
    Int Immunopharmacol; 2021 Aug; 97():107702. PubMed ID: 33930706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
    Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study.
    Almoosa Z; Saad M; Qara S; Mustafa M; Mansour A; Alshab D; Alhashem J; ALKhawajah S; Alkhalifah S; ALmarzooq M; ALzain M; Anshasi N; Ahmed G; Mutair AA
    J Infect Public Health; 2021 Sep; 14(9):1247-1253. PubMed ID: 34464921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.
    Solaymani-Dodaran M; Ghanei M; Bagheri M; Qazvini A; Vahedi E; Hassan Saadat S; Amin Setarehdan S; Ansarifar A; Biganeh H; Mohazzab A; Khalili D; Hosein Ghazale A; Reza Heidari M; Taheri A; Khoramdad M; Mahdi Asadi M; Nazemieh M; Varshochi M; Abbasian S; Bakhtiari A; Mosaed R; Hosseini-Shokouh SJ; Shahrokhi M; Yassin Z; Ali Zohal M; Qaraati M; Rastgoo N; Sami R; Javad Eslami M; Asghari A; Namazi M; Ziaie S; Jafari-Moghaddam R; Kalantari S; Memarian M; Khodadadi J; Hossein Afshari M; Momen-Heravi M; Behzadseresht N; Reza Mobayen A; Mozafari A; Movasaghi F; Haddadzadeh Shoushtari M; Moazen J
    Int Immunopharmacol; 2021 Jun; 95():107522. PubMed ID: 33735712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.